11/12
07:00 am
btai
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
Medium
Report
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
11/8
07:00 am
btai
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Medium
Report
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
11/5
12:13 pm
btai
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know [Yahoo! Finance]
Low
Report
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know [Yahoo! Finance]
10/29
07:00 am
btai
BioXcel Therapeutics to Present at ThinkEquity Conference
Medium
Report
BioXcel Therapeutics to Present at ThinkEquity Conference
10/21
08:07 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
10/15
07:00 am
btai
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
Medium
Report
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
9/19
07:00 am
btai
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
Low
Report
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
9/6
08:08 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
High
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
9/5
07:00 am
btai
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Medium
Report
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
8/30
12:16 pm
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $7.00 price target on the stock.
Medium
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $7.00 price target on the stock.